On Jun. 11, 2020, Innovation Pharma announced the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application. The proposed research aimed to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing.